Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Change in Receivables (2016 - 2025)

Ocular Therapeutix has reported Change in Receivables over the past 13 years, most recently at -$118000.0 for Q4 2025.

  • Quarterly results put Change in Receivables at -$118000.0 for Q4 2025, down 105.48% from a year ago — trailing twelve months through Dec 2025 was -$1.7 million (down 127.99% YoY), and the annual figure for FY2025 was -$1.7 million, down 127.99%.
  • Change in Receivables for Q4 2025 was -$118000.0 at Ocular Therapeutix, down from $356000.0 in the prior quarter.
  • Over the last five years, Change in Receivables for OCUL hit a ceiling of $6.2 million in Q2 2023 and a floor of -$7.2 million in Q1 2025.
  • Median Change in Receivables over the past 5 years was $1.1 million (2021), compared with a mean of $919900.0.
  • Peak annual rise in Change in Receivables hit 11766.67% in 2025, while the deepest fall reached 2052.86% in 2025.
  • Ocular Therapeutix's Change in Receivables stood at $1.6 million in 2021, then dropped by 3.79% to $1.5 million in 2022, then surged by 70.06% to $2.6 million in 2023, then dropped by 16.87% to $2.2 million in 2024, then tumbled by 105.48% to -$118000.0 in 2025.
  • The last three reported values for Change in Receivables were -$118000.0 (Q4 2025), $356000.0 (Q3 2025), and $5.2 million (Q2 2025) per Business Quant data.